- ホーム
- > 洋書
- > 英文書
- > Science / Mathematics
Full Description
In the lung, more recent data have been accumulated on lung stem cell biology/function and the potential applications of stem cells in pulmonary diseases that are facilitated by the recent development of a broad range of cutting edge in vitro and in vivo research tools and approaches, including mouse and human organoid cultures, genetic editing in vitro and in vivo, human induced pluripotent cell (iPS cell) models of disease, haploid cells for genetic as well as compound screening paradigms, genetically engineered mice, and stem cell transplantation to cure diseases.
Stem Cell Innovation in Health and Disease: Volume 2: The Lung, contains two major sections describing cutting edge research for understanding stem cell functions in the lung and respiratory system, and for developing methods to bring stem cells from bench to bedside; respectively. Each section includes insights ranging from using mouse and human organoid cultures, genetic editing in vitro and in vivo, and human induced pluripotent cells (iPSCs) to study stem cell functions and model lung diseases, through the cutting-edge research aiming to bring stem cells from bench to bedside, including the potential application of iPSCs, ESCs and blood stem cells (stem cell transplants) in the treatment of lung diseases/disorders. This book, therefore, discusses the fact-based promise of stem cells and regenerative medicine in the lung in the real world.
Contents
Cutting edge Research on the lung stem cell functions1. Lung organoid-based modality of lung function, cellular processes and stem cell functions2. Pulmonary organoid culture system in pulmonary pathology and genetic screening
Cutting edge Research on stem cell application in the lung diseases (from bench to bed)3. Pulmonary organoid culture as innovative test-bed for basic and translational approaches (e.g., disease modeling, drug screening, etc.)4. Contributions of lung stem cell engineering to disease-specific cell line models and new therapies of lung diseases5. Preclinical and clinical applications of innovative gene editing technologies (ZFN, TALEN and CRISPR/Cas9 systems) in respiratory diseases6. iPSCs as an inexhaustible source of disease- or patient-specific stem cell models for lung development, disease and therapy and drug development from bench to bed7. The gold standard embryonic stem cells in lung repair and diseases8. Hematopoietic stem cell roles in the treatment of respiratory diseases9. Clinical potentials of human mesenchymal stem and mesenchymal stromal cells in lung diseases10. General Discussion, Conclusion Remarks and Future Direction
